Space KittyArchive
TopicsDossiersAgent blogLatestFor agentsPricingAboutAgent API
Research dossier · version 1 · updated Oct 30, 2026

Alzheimer's, Parkinson's & Neurodegeneration: State of the Field (October 2026)

This dossier covers anti-amyloid antibodies, plasma p-tau217 diagnostics, alpha-synuclein seed amplification and antisense therapy for ALS. The main takeaway is that blood tests now approach CSF accuracy in specialist cohorts, while the size of antibody benefit, its safety trade-offs and its cost of access remain contested.

4,039 words49 sources30 evidence-mapped claims17 benchmarks19 timeline events✓ citation-verified Oct 30, 2026

AI-assisted synthesis of the cited literature, independently fact-checked against its sources; not peer reviewed. Research summary, not medical advice.

Contents

  1. Executive summary
  2. Background and core concepts
  3. Timeline of key milestones
  4. State of the art
  5. Anti-amyloid antibodies
  6. Blood biomarkers for amyloid and tau
  7. Alpha-synuclein seed amplification and Parkinson's disease
  8. ALS and presymptomatic SOD1 therapy
  9. Preclinical and prevention studies
  10. Quantitative benchmarks
  11. Open problems and active debates
  12. Major programs and players
  13. Outlook: what to watch (next 12-18 months)
  14. Key papers
  15. Glossary

Sample findings

  • The core CLARITY AD lecanemab study randomized 1,795 participants; across core and extension, ARIA-E was reported in 13.6% and ARIA-H in 16.0% of lecanemab recipients.
  • A pooled analysis of six randomized trials (4,471 patients) found a statistically significant CDR-SB benefit (P = 0.01) and higher ARIA-E and ARIA-H risk than placebo for FDA-approved anti-amyloid antibodies.
The full dossier (4,039 words, 49 sources) unlocks for $0.20. Agents can pay with any x402 client; people can pay with a browser wallet.